Vimal Mehta - Mar 20, 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Signature
/s/ Richard Steinhart, as Attorney in Fact for Vimal Mehta, Ph.D.
Stock symbol
BTAI
Transactions as of
Mar 20, 2023
Transactions value $
-$1,198,713
Form type
4
Date filed
3/22/2023, 07:30 PM
Previous filing
Mar 16, 2023
Next filing
May 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise $12.3K +30K +147.1% $0.41* 50.4K Mar 20, 2023 Direct
transaction BTAI Common Stock Sale -$449K -24.7K -48.95% $18.20 25.7K Mar 20, 2023 Direct F1, F2
transaction BTAI Common Stock Sale -$101K -5.33K -20.73% $18.86 20.4K Mar 20, 2023 Direct F1, F3
transaction BTAI Common Stock Sale -$71K -3.9K -19.1% $18.22 16.5K Mar 20, 2023 Direct F1, F4
transaction BTAI Common Stock Sale -$11.4K -604 -3.66% $18.88 15.9K Mar 20, 2023 Direct F1, F5
transaction BTAI Common Stock Options Exercise $12.3K +30K +188.75% $0.41* 45.9K Mar 21, 2023 Direct
transaction BTAI Common Stock Sale -$573K -29.1K -63.41% $19.70 16.8K Mar 21, 2023 Direct F1, F6
transaction BTAI Common Stock Sale -$18.1K -900 -5.36% $20.15 15.9K Mar 21, 2023 Direct F1, F7
holding BTAI Common Stock 8.55M Mar 20, 2023 See footnote F8
holding BTAI Common Stock 2K Mar 20, 2023 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Stock Option (Right to Buy) Options Exercise $0 -30K -7.25% $0.00 384K Mar 20, 2023 Common Stock 30K $0.41 Direct F9
transaction BTAI Stock Option (Right to Buy) Options Exercise $0 -30K -7.81% $0.00 354K Mar 21, 2023 Common Stock 30K $0.41 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.75 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.75 to $19.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.79 to $18.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.81 to $19.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.06 to $20.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.08 to $20.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F8 These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
F9 The option is fully vested and exercisable.